Brokerages Anticipate Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to Announce -$0.67 Earnings Per Share

Wall Street analysts expect that Karyopharm Therapeutics Inc. (NASDAQ:KPTI) will post ($0.67) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Karyopharm Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.56) and the lowest estimate coming in at ($0.73). Karyopharm Therapeutics posted earnings per share of ($0.73) during the same quarter last year, which indicates a positive year-over-year growth rate of 8.2%. The company is expected to issue its next earnings results on Monday, November 1st.

On average, analysts expect that Karyopharm Therapeutics will report full-year earnings of ($2.81) per share for the current year, with EPS estimates ranging from ($2.99) to ($2.50). For the next fiscal year, analysts expect that the firm will post earnings of ($2.07) per share, with EPS estimates ranging from ($2.77) to ($1.69). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Karyopharm Therapeutics.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, August 5th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.01. Karyopharm Therapeutics had a negative return on equity of 7,204.16% and a negative net margin of 203.25%.

A number of research firms have issued reports on KPTI. Royal Bank of Canada downgraded Karyopharm Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $17.00 to $8.00 in a report on Thursday, August 5th. HC Wainwright decreased their price objective on Karyopharm Therapeutics from $49.00 to $26.00 and set a “buy” rating for the company in a report on Friday, August 6th. Zacks Investment Research downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 6th. JPMorgan Chase & Co. downgraded Karyopharm Therapeutics from an “overweight” rating to an “underweight” rating in a report on Friday, August 6th. Finally, Robert W. Baird decreased their price objective on Karyopharm Therapeutics from $30.00 to $17.00 and set an “outperform” rating for the company in a report on Friday, August 6th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Karyopharm Therapeutics has a consensus rating of “Hold” and a consensus price target of $18.00.

Shares of Karyopharm Therapeutics stock opened at $5.59 on Friday. The company has a quick ratio of 4.64, a current ratio of 4.71 and a debt-to-equity ratio of 2.33. The company has a market cap of $422.03 million, a PE ratio of -2.00 and a beta of 0.21. The business has a 50 day moving average of $6.89 and a 200 day moving average of $9.04. Karyopharm Therapeutics has a 52 week low of $4.42 and a 52 week high of $18.00.

Several large investors have recently modified their holdings of KPTI. Goldman Sachs Group Inc. boosted its position in shares of Karyopharm Therapeutics by 14.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,211,971 shares of the company’s stock valued at $12,750,000 after buying an additional 157,209 shares during the last quarter. Morgan Stanley boosted its position in shares of Karyopharm Therapeutics by 128.6% during the first quarter. Morgan Stanley now owns 1,698,473 shares of the company’s stock valued at $17,868,000 after buying an additional 955,560 shares during the last quarter. Frontier Capital Management Co. LLC boosted its position in shares of Karyopharm Therapeutics by 21.9% during the second quarter. Frontier Capital Management Co. LLC now owns 1,488,939 shares of the company’s stock valued at $15,366,000 after buying an additional 267,312 shares during the last quarter. Weiss Multi Strategy Advisers LLC boosted its position in shares of Karyopharm Therapeutics by 28.1% during the first quarter. Weiss Multi Strategy Advisers LLC now owns 32,143 shares of the company’s stock valued at $338,000 after buying an additional 7,047 shares during the last quarter. Finally, Moors & Cabot Inc. boosted its position in shares of Karyopharm Therapeutics by 28.5% during the first quarter. Moors & Cabot Inc. now owns 18,950 shares of the company’s stock valued at $199,000 after buying an additional 4,200 shares during the last quarter. Hedge funds and other institutional investors own 78.06% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics, Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).

Read More: Death Cross

Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.